Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy

International Journal of Cancer

Volumn 136, Issue 2, 2015, Pages 278-288

  Rödel, Franz ^a   Wieland, Ulrike ^b   Fraunholz, Ingeborg ^a   Kitz, Julia ^c   Rave Fränk, Margret ^c   Wolff, Hendrik A ^c   Weiss, Christian ^a   Wirtz, Ralph ^d   Balermpas, Panagiotis ^a   Fokas, Emmanouil ^a   Rödel, Claus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^d St Elisabeth Hospital   (Germany)

Author keywords

anal carcinoma; chemoradiotherapy; HPV; local control; overall survival; p16INK4a

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLUOROURACIL; MITOMYCIN; VIRUS DNA; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; ANAL SQUAMOUS CELL CARCINOMA; ANUS CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 44; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 81; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE; VIRUS LOAD; WART VIRUS; ANUS NEOPLASMS; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CLASSIFICATION; COMPLICATION; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MORTALITY; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PROGNOSIS; VIROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VIRAL LOAD;

EID: 84922311673     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28979     Document Type: Article

References (50)

1. Ajani JA, Winter KA, Gunderson LL, et al., Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008; 299: 1914-21.
2. zur Hausen H,. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-50.
3. Daling JR, Madeleine MM, Johnson LG, et al., Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-80.
4. Frisch M, Biggar RJ,. Aetiological parallel between tonsillar and anogenital squamous-cell carcinomas. Lancet 1999; 354: 1442-43.
5. Palefsky JM, Giuliano AR, Goldstone S, et al., HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-85.
6. De Vuyst H, Clifford G, Li N, et al., HPV infection in europe. Eur J Cancer 2009; 45: 2632-39.
7. Skamperle M, Kocjan BJ, Maver PJ, et al., Human papillomavirus (HPV) prevalence and HPV type distribution in cervical, vulvar, and anal cancers in central and eastern Europe. Acta Dermatovenerol Alp Panonica Adriat 2013; 22: 1-5.
8. Ang KK, Harris J, Wheeler R, et al., Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
9. Rischin D, Young RJ, Fisher R, et al., Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-48.
10. Vosmik M, Laco J, Sirak I, et al., Prognostic significance of human papillomavirus (HPV) status and expression of selected markers (HER2/neu, EGFR, VEGF, CD34, p63, p53 and Ki67/MIB-1) on outcome after (Chemo-) radiotherapy in patients with squamous cell carcinoma of uterine cervix. Pathol Oncol Res 2013; 20: 131-7.
11. Kimple RJ, Smith MA, Blitzer GC, et al., Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res 2013; 73: 4791-800.
12. Rieckmann T, Tribius S, Grob TJ, et al., HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity. Radiother Oncol 2013; 107: 242-46.
13. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al., Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-98.
14. Kim JY, Park S, Nam BH, et al., Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. J Clin Oncol 2009; 27: 5088-93.
15. Hoffmann M, Ihloff AS, Gorogh T, et al., p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-602.
16. Yugawa T, Kiyono T,. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol 2009; 19: 97-113.
17. Zhang HS, Postigo AA, Dean DC,. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999; 97: 53-61.
18. Yhim HY, Lee NR, Song EK, et al., The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer 2011; 129: 1752-60.
19. Brueckl WM, Schoeberl A, Wirtz RM, et al., Increased vascular-endothelial growth factor (VEGF) tumor expression and response to epidermal growth factor receptor (EGF-R) inhibitor erlotinib in non-small cell lung cancer (NSCLC). J Thorac Oncol 2008; 3: 314-16.
20. Schmitt M, Bravo IG, Snijders PJ, et al., Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006; 44: 504-12.
21. Schmitt M, Dondog B, Waterboer T, et al., Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol 2008; 46: 1050-59.
22. Bouvard V, Baan R, Straif K, et al., A review of human carcinogens-Part B: Biological agents. Lancet Oncol 2009; 10: 321-22.
23. Wieland U, Ritzkowsky A, Stoltidis M, et al., Papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol 2000; 115: 124-28.
24. Kreuter A, Potthoff A, Brockmeyer NH, et al., Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol 2010; 162: 1269-77.
25. van Duin M, Snijders PJ, Schrijnemakers HF, et al., Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer 2002; 98: 590-95.
26. Weissenborn SJ, Wieland U, Junk M, et al., Quantification of beta-human papillomavirus DNA by real-time PCR. Nat Protoc 2010; 5: 1-13.
27. Walline HM, Komarck C, McHugh JB, et al., High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers: comparison of multiple methods. JAMA Otolaryngol Head Neck Surg 2013; 139: 1320-27.
28. Salazar CR, Anayannis N, Smith RV, et al., Combined p16 and human papillomavirus testing predicts head and neck cancer survival. Int J Cancer, in press, doi: 10.1002/ijc.28876.
29. De Vuyst H, Clifford GM, Nascimento MC, et al., Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009; 124: 1626-36.
30. Valmary-Degano S, Jacquin E, Pretet JL, et al., Signature patterns of human papillomavirus type 16 in invasive anal carcinoma. Hum Pathol 2013; 44: 992-1002.
31. Wong AK, Chan RC, Aggarwal N, et al., Human papillomavirus genotypes in anal intraepithelial neoplasia and anal carcinoma as detected in tissue biopsies. Mod Pathol 2010; 23: 144-50.
32. Gilbert DC, Williams A, Allan K, et al., p16, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiother Oncol 2013; 109: 146-51.
33. Moody CA, Laimins LA,. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-60.
34. Dyson N, Howley PM, Munger K, et al., The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-37.
35. Scheffner M, Werness BA, Huibregtse JM, et al., The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
36. McLaughlin-Drubin ME, Munger K,. Oncogenic activities of human papillomaviruses. Virus Res 2009; 143: 195-208.
37. Kreuter A, Brockmeyer NH, Weissenborn SJ, et al., Penile intraepithelial neoplasia is frequent in HIV-positive men with anal dysplasia. J Invest Dermatol 2008; 128: 2316-24.
38. Kreuter A, Jesse M, Potthoff A, et al., Expression of proliferative biomarkers in anal intraepithelial neoplasia of HIV-positive men. J Am Acad Dermatol 2010; 63: 490-98.
39. Kreuter A, Wieland U, Gambichler T, et al., p16ink4a expression decreases during imiquimod treatment of anal intraepithelial neoplasia in human immunodeficiency virus-infected men and correlates with the decline of lesional high-risk human papillomavirus DNA load. Br J Dermatol 2007; 157: 523-30.
40. Hoots BE, Palefsky JM, Pimenta JM, et al., Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int J Cancer 2009; 124: 2375-83.
41. Glynne-Jones R, Sebag-Montefiore D, Adams R, et al., Prognostic factors for recurrence and survival in anal cancer: generating hypotheses from the mature outcomes of the first United Kingdom Coordinating Committee on Cancer Research Anal Cancer Trial (ACT I). Cancer 2013; 119: 748-55.
42. Fakhry C, Westra WH, Li S, et al., Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-69.
43. Hampson L, El Hady ES, Moore JV, et al., The HPV16 E6 and E7 proteins and the radiation resistance of cervical carcinoma. FASEB J 2001; 15: 1445-47.
44. Pang E, Delic NC, Hong A, et al., Radiosensitization of oropharyngeal squamous cell carcinoma cells by human papillomavirus 16 oncoprotein E6. Int J Radiat Oncol Biol Phys 2011; 79: 860-65.
45. Gupta AK, Lee JH, Wilke WW, et al., Radiation response in two HPV-infected head-and-neck cancer cell lines in comparison to a non-HPV-infected cell line and relationship to signaling through AKT. Int J Radiat Oncol Biol Phys 2009; 74: 928-33.
46. Lewis JS, Jr, Chernock RD, Ma XJ, et al., Partial p16 staining in oropharyngeal squamous cell carcinoma: extent and pattern correlate with human papillomavirus RNA status. Mod Pathol 2012; 25: 1212-20.
47. Silling S, Kreuter A, Hellmich M, et al., Human papillomavirus oncogene mRNA testing for the detection of anal dysplasia in HIV-positive men who have sex with men. J Clin Virol 2012; 53: 325-31.
48. Rayess H, Wang MB, Srivatsan ES,. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130: 1715-25.
49. Benson E, Li R, Eisele D, et al., The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol 2014; 50: 565-74.
50. van Kempen PM, Noorlag R, Braunius WW, et al., Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma: a systematic review. Epigenetics 2014; 9: 194-203.